-Bloomberg
Silence Therapeutics Announces JAMA Publication Of Additional APOLLO Phase 1 Data For Zerlasiran In Subjects With Elevated Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered